| ropinirole IR / Generic mfg. |
NCT00593606: Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine |
|
|
| Completed | 3b | 124 | RoW | Rotigotine, Neupro | UCB Pharma | Parkinson's Disease | 12/07 | 12/07 | | |
NCT01723904: A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease |
|
|
| Completed | 3b | 90 | RoW | Rotigotine, Neupro | UCB BIOSCIENCES GmbH, Otsuka Pharmaceutical Co., Ltd. | Advanced Parkinson's Disease | 03/13 | 04/13 | | |
NCT00381472: Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa |
|
|
| Completed | 3 | 393 | US, Europe | Ropinirole | GlaxoSmithKline | Parkinson Disease | | 12/04 | | |
NCT00243971 / 2004-002609-66: A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease |
|
|
| Completed | 3 | | Europe | SPM 962 | UCB Pharma | Parkinson's Disease | 10/05 | 10/05 | | |
NCT00363727: Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's |
|
|
| Completed | 3 | 209 | US | ropinirole controlled-release (REQUIP CR) for RLS | GlaxoSmithKline | Parkinson's Disease, Parkinson Disease, Dyskinesias | 01/06 | 01/06 | | |
NCT00275275: Pramipexole Conversion to Ropinirole Controlled Release (CR) |
|
|
| Completed | 3 | 61 | US | Requip PR, Requip 24-hour prolonged release (PR)., Mirapex, Pramipexole | Rajesh Pahwa, MD, GlaxoSmithKline | Parkinson Disease | 05/08 | 05/08 | | |
|
NCT00650104: Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 |
|
|
| Completed | 3 | 76 | US | Ropinirole XL (formerly CR) | GlaxoSmithKline | Parkinson Disease | 03/09 | 03/09 | | |
NCT00632736: An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease |
|
|
| Completed | 3 | 419 | US, Europe | Ropinirole XL (formerly CR) | GlaxoSmithKline | Parkinson Disease, Parkinson's Disease | 03/10 | 03/10 | | |
NCT01628926: A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients |
|
|
| Completed | 3 | 420 | Japan | SPM 962, Ropinirole, Placebo | Otsuka Pharmaceutical Co., Ltd. | Parkinson's Disease | 05/11 | 05/11 | | |
NCT01154166: A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa |
|
|
| Completed | 3 | 347 | RoW | ReQuip PR, Placebo | GlaxoSmithKline | Parkinson Disease | 09/11 | 09/11 | | |
| Completed | 3 | 80 | Europe | piribedil, Clarium®, pramipexole or ropinirole | Desitin Arzneimittel GmbH, FGK Clinical Research GmbH | Idiopathic Parkinson's Disease | 12/11 | 12/11 | | |
|
| Completed | 3 | 679 | US, Canada, Europe, RoW | Safinamide (as add-on therapy), Apokyn, Parlodel, Mirapex, Requip, Cabergoline (not approved in US), Lisuride (not approved in US), Pergolide (withdrawn from US Market March 2007) | Newron Pharmaceuticals SPA | Idiopathic Parkinson's Disease | 01/12 | 03/12 | | |
|
|
|
|
|
NCT01536574: Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 |
|
|
| Completed | 3 | 295 | RoW | Requip PR | GlaxoSmithKline | Parkinson Disease | 03/12 | 03/12 | | |
